Pipeline

Clinical Trial Information

Ganaxolone is being developed in intravenous (IV) and oral formulations intended to maximize therapeutic reach to patient populations in both acute and chronic care settings.

Marinus completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder in 2020, is planning to conduct a Phase 3 trial in tuberous sclerosis complex, and a Phase 3 trial in refractory status epilepticus is ongoing.